Loading...
Oryzon Genomics S.A.
ORYZF•PNK
Healthcare
Biotechnology
$3.28
$-0.00(-0.08%)
Oryzon Genomics S.A. (ORYZF) Financial Performance & Income Statement Overview
Review Oryzon Genomics S.A.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-48.15%
↓ 48.15%
Operating Income Growth
2.77%
↑ 2.77%
Net Income Growth
-9.32%
↓ 9.32%
Operating Cash Flow Growth
-889.58%
↓ 889.58%
Operating Margin
6.70%
↑ 6.70%
Gross Margin
95.85%
↑ 95.85%
Net Profit Margin
-99.60%
↓ 99.60%
ROE
-4.71%
↓ 4.71%
ROIC
0.28%
↑ 0.28%
Oryzon Genomics S.A. (ORYZF) Income Statement & Financial Overview
Review Oryzon Genomics S.A.'s (ORYZF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.36M | $0.00 | $4.11M | $0.00 |
| Cost of Revenue | $302189.00 | $0.00 | $170475.00 | $0.00 |
| Gross Profit | $7.06M | $0.00 | $3.94M | $0.00 |
| Gross Profit Ratio | $0.96 | $0.00 | $0.96 | |
| R&D Expenses | $6.83M | $1.92M | $647984.00 | $2.27M |
| SG&A Expenses | $500125.00 | $879000.00 | $296308.00 | $743605.00 |
| Operating Expenses | $1.70M | $2.79M | $3.10M | $3.01M |
| Total Costs & Expenses | $2.000M | $2.79M | -$835749.00 | $3.01M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $36937.00 | $0.00 | $14722.00 | $0.00 |
| EBITDA | $5.24M | -$2.79M | $850470.00 | -$3.01M |
| EBITDA Ratio | $0.71 | $0.21 | ||
| Operating Income | $5.36M | -$2.79M | $835748.00 | -$3.01M |
| Operating Income Ratio | $0.73 | $0.20 | ||
| Other Income/Expenses (Net) | -$8.47M | $1.42M | -$2.74M | $2.07M |
| Income Before Tax | -$3.12M | -$1.38M | -$1.90M | -$946956.00 |
| Income Before Tax Ratio | -$0.42 | -$0.46 | ||
| Income Tax Expense | $1.91M | $0.00 | -$2.008M | $120631.00 |
| Net Income | -$1.21M | -$1.38M | $107172.00 | -$1.07M |
| Net Income Ratio | -$0.16 | $0.03 | ||
| EPS | -$0.02 | -$0.02 | $0.002 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.02 | $0.002 | -$0.02 |
| Weighted Avg Shares Outstanding | $64.37M | $63.38M | $61.22M | $61.22M |
| Weighted Avg Shares Outstanding (Diluted) | $64.37M | $63.38M | $61.22M | $61.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan